Stoke Therapeutics advances TANGO ASO for Dravet, with Zorevunersen Phase 3 data showing seizure reduction and a delayed 2027 ...

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...

At Praxis, Dr. Devinsky will be part of the group leading clinical strategy and global medical affairs, guiding program architecture, evidence generation, and external scientific engagement as the ...

Stoke Therapeutics Inc.’s speeded-up timeline for zorevunersen, the antisense oligonucleotide in development with Biogen Inc.

Encoded Therapeutics, Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the U.S. Food and Drug ...

The event, which organizers declared “wildly successful,” raised more than $300,000 for epilepsy research and education.

WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...

The biotechnology company now expects to complete enrollment of 150 patients in the second quarter of 2026, with data readout anticipated in mid-2027. Stoke plans to initiate a rolling New Drug ...

Stoke Therapeutics and the FDA were unable to reach agreement on an expedited submission for the company’s severe epilepsy ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...